N
RNAM

Natixis’s Avidity Biosciences RNAM Stock Holding History

Natixis’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,325
Closed -$673K – 1285
2025
Q4 		$673K Buy
+9,325
New +$602K ﹤0.01% 787
2024
Q4 		– Sell
-1,675
Closed -$76.9K – 1169
2024
Q3 		$76.9K Sell
1,675
-90
-5% -$3.91K ﹤0.01% 763
2024
Q2 		$72.1K Sell
1,765
-2,118
-55% -$60.8K ﹤0.01% 762
2024
Q1 		$99.1K Sell
3,883
-93
-2% -$1.46K ﹤0.01% 775
2023
Q4 		$36K Sell
3,976
-209
-5% -$1.4K ﹤0.01% 848
2023
Q3 		$26.7K Sell
4,185
-14
-0.3% -$121 ﹤0.01% 857
2023
Q2 		$46.6K Sell
4,199
-946
-18% -$11.9K ﹤0.01% 852
2023
Q1 		$79K Sell
5,145
-320
-6% -$7.04K ﹤0.01% 803
2022
Q4 		$121K Buy
+5,465
New +$81.5K ﹤0.01% 860

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Natixis's RNAM Position: Q1 2026 in Review

Natixis sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 9,325 shares — an estimated $673K sold.

Natixis first reported a position in RNAM in Q4 2022 and held it in 9 quarters. The position peaked at $673K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Natixis reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 9,325 Avidity Biosciences shares in Q1 2026, an estimated $673K.
  • Natixis first reported a position in Avidity Biosciences in Q4 2022 and held it in 9 quarters.
  • Natixis's Avidity Biosciences position peaked at $673K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.